Amtagvi® (lifileucel)
for Skin Cancer

Amtagvi (lifileucel) is a tumor-derived autologous T cell immunotherapy given as an infusion to treat adults with melanoma that cannot be surgically removed, has spread, and has not responded to PD-1 blocking drugs or BRAF inhibitors. It is derived from T cells taken from the patient's tumor, which may recognize and kill cancer cells. While the exact mechanism is unknown, Amtagvi aims to enhance the body's immune response to fight melanoma.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Skin Cancer